Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Zentalis Pharmaceuticals, Inc. | SVP, Clinical Development | Stock Option (Right to Buy) | 24.2K | $1.16M | $47.80 | Feb 10, 2022 | Direct |
Zentalis Pharmaceuticals, Inc. | SVP, Clinical Development | Common Stock | 16K | $164K | $10.29 | Feb 14, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ZNTL | Zentalis Pharmaceuticals, Inc. | Feb 10, 2022 | 4 | -$30.2K | 4 | Feb 14, 2022 | SVP, Clinical Development |
ZNTL | Zentalis Pharmaceuticals, Inc. | Jan 18, 2022 | 15 | -$1.3M | 4 | Jan 20, 2022 | SVP, Clinical Development |